May 18, 2026 08:00AM
May 14, 2026 10:55AM
May 12, 2026 09:04AM
May 12, 2026 09:00AM
Apr 30, 2026 09:00AM
Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Feb 27, 2026 10:04AM
Feb 27, 2026 10:00AM
Jan 8, 2026 10:30AM
Dec 17, 2025 06:45AM
Dec 10, 2025 06:30PM
Dec 5, 2025 08:00AM
Nov 21, 2025 01:24PM FDA approves PADCEV plus Keytruda for bladder cancer patients
Nov 21, 2025 01:24PM
Oct 23, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
Oct 19, 2025 07:30PM
Oct 14, 2025 08:00PM Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
Oct 8, 2025 07:30PM
May 1, 2025 09:00AM
Feb 12, 2025 06:32PM
Jan 8, 2025 06:30PM
Dec 5, 2024 08:49AM
Nov 20, 2024 01:00PM
Oct 18, 2024 02:13PM Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
Oct 10, 2024 01:00PM
Sep 24, 2024 02:05AM
Sep 18, 2024 07:30PM
Sep 4, 2024 08:00AM
Aug 27, 2024 07:30PM
Jul 26, 2024 11:39AM
May 30, 2024 10:30PM U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
Apr 23, 2024 07:30PM
Mar 28, 2024 11:00AM
Mar 26, 2024 08:30AM
Mar 22, 2024 08:00AM
Mar 11, 2024 09:00AM
Feb 15, 2024 06:30PM
Feb 1, 2024 07:00AM Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
Jan 30, 2024 09:00PM
Jan 26, 2024 12:01PM
Jan 26, 2024 12:00PM
Jan 26, 2024 12:00PM
Jan 8, 2024 06:30PM
Dec 8, 2023 01:18PM
Nov 16, 2023 10:33PM Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Nov 15, 2023 06:30PM

322,241 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All